Related Experiment Videos
[Eculizumab in paroxysmal nocturnal hemoglobinuria]
Gérard Socié1, Nathalie Varoqueaux, Régis Peffault de Latour
1Service d'hématologie-greffe, Inserm U728, Hôpital Saint-Louis, AP-HP, 1, avenue Claude Vellefaux, 75010 Paris, France. gerard.socie@sls.aphp.fr
Abstract:
Paroxysmal nocturnal hemoglobinuria is a rare acquired clonal of the hematopoietic stem cell due to acquired mutation of the PIG-A gene. This results in the lack of two GPI-anchored membrane proteins involved in the inhibition of complement attack, thus explaining red cells hemolysis. The development of an anti-C5 monoclonal antibody (eculizumab) had profoundly modified the treatment of the the hemolytic form of the disease.